Fate Therapeutics Inc (FATE) Stock Analysis

Fate Therapeutics Inc (FATE) is a publicly traded company in the HEALTHCARE sector. It trades at $2.57, carries a market capitalization of $319.37M. This page summarizes the public market data, fundamentals, and frequently asked questions for FATE, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Fate Therapeutics Inc currently has a Bullish sentiment score of 0.19.

About Fate Therapeutics Inc

Fate Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing next-generation programmed cellular immunotherapies for cancer and immune disorders. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, Fate is pioneering the creation of off-the-shelf therapies designed to enhance immune system responses. The company boasts a strong pipeline of therapeutic candidates aimed at addressing both h...

GNG Research Analysis

GNG Research scores Fate Therapeutics Inc (FATE) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FATE.

Frequently Asked Questions

Does FATE pay dividends?

Fate Therapeutics Inc (FATE) does not currently pay a regular dividend.

What is FATE's market cap?

Fate Therapeutics Inc (FATE) has a market capitalization of $319.37M with a current stock price of $2.57.